News Merck confirms its interest in buying SpringWorks Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.
News Ten years on, Roche jettisons InterMune and Esbriet in US It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now, it's sold the business.
News Bain buys Japanese pharma Mitsubishi Tanabe for $3.4bn Bain Capital has agreed to buy Mitsubishi Tanabe for around $3.4 bn, setting up one of the largest private equity buyouts in Japan's health sector.
News Liva buys Momenta to bolster digital health platform Liva Healthcare has acquired Momenta to create one of the largest providers of digital healthy lifestyle services to the NHS in England.
News Troubled 23andMe is exploring a sale of the business Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.
News Sage rejects Biogen takeover and launches review Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.
News AZ claims another win for Imfinzi in frontline liver cancer AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.